Zobrazeno 1 - 10
of 2 334
pro vyhledávání: '"benralizumab"'
Publikováno v:
Romanian Journal of Internal Medicine, Vol 62, Iss 3, Pp 356-361 (2024)
Eosinophilic Esophagitis is a widely-recognized immune-mediated esophagus disease with distinct clinical and histopathological features, exhibiting an increased global incidence. Therapeutic options encompass either dietary measures or pharmacologica
Externí odkaz:
https://doaj.org/article/f32909de34704dee933a6626ba3721c7
Autor:
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential p
Externí odkaz:
https://doaj.org/article/8a23af9f1a724ed69d43d34d79739f8c
Autor:
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 557-572 (2024)
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich,
Externí odkaz:
https://doaj.org/article/4876db04923144e59915c062279f0c76
Autor:
Masamitsu Hamakawa, Tadashi Ishida
Publikováno v:
Respirology Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Key message It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co‐morbidities. If the initial bio
Externí odkaz:
https://doaj.org/article/32c9d6cd1feb49aab8573c72ecf3f4ea
Autor:
Marco Caminati, MD, Lucia Federica Carpagnano, MD, Chiara Alberti, MSc, Francesco Amaddeo, PhD, Riccardo Bixio, MD, Federico Caldart, MD, Lucia De Franceschi, PhD, Micol Del Giglio, PhD, Giuliana Festi, MD, Simonetta Friso, PhD, Luca Frulloni, MD, Paolo Gisondi, MD, Mauro Krampera, PhD, Giuseppe Lippi, PhD, Claudio Micheletto, MD, Giorgio Piacentini, PhD, Patrick Pinter, MD, Maurizio Rossini, PhD, Michele Schiappoli, MD, Cristina Tecchio, PhD, Laura Tenero, PhD, Elisa Tinazzi, PhD, Gianenrico Senna, MD, Matilde Carlucci, MD
Publikováno v:
World Allergy Organization Journal, Vol 17, Iss 8, Pp 100928- (2024)
Hypereosinophilic syndromes (HES) represent a group of rare dis-immune conditions characterized by blood hyper-eosinophilia and eosinophilic related burden. Especially the idiopathic subtype (I-HES) is particularly difficult to diagnose because of it
Externí odkaz:
https://doaj.org/article/dbbf5baf061344db9728a002cad44571
Autor:
Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 273-290 (2024)
Paolo Cameli,1 Maria Aliani,2 Elena Altieri,3 Pietro Bracciale,4 Luisa Brussino,5 Maria Filomena Caiaffa,6 Giorgio Walter Canonica,7,8 Cristiano Caruso,9 Stefano Centanni,10 Maria D’Amato,11 Fausto De Michele,12 Stefano Del Giacco,13 Fabiano Di Mar
Externí odkaz:
https://doaj.org/article/ac1f80ecdea74103aab26a40cad5bf26
Autor:
Moritz Z. Kayser, Hendrik Suhling, Jan Fuge, Christopher A. Hinze, Nora Drick, Nikolaus Kneidinger, Jürgen Behr, Christian Taube, Tobias Welte, Ina Haasler, Katrin Milger
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. W
Externí odkaz:
https://doaj.org/article/9b65f82e70434ca195edfb5cf288a4e3
Publikováno v:
Фармакоэкономика, Vol 16, Iss 4, Pp 527-536 (2024)
Objective: to evaluate the clinical and economic effectiveness of benralizumab in comparison with standard therapy in patients with severe bronchial asthma (SBA) with an eosinophilic phenotype in the Russian Federation.Material and methods. A clinica
Externí odkaz:
https://doaj.org/article/202ddd6e43c44c1fb5bc1fe93988acc6
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background We aimed to clarify comprehensively the safety profiles of anti-IL-5 drugs and pinpoint potential safety concerns that may arise in their post-marketing phase. Methods Two researchers conducted comprehensive searches of PubMed, EM
Externí odkaz:
https://doaj.org/article/d3380dc9452943b7a3ae28a3c88a0820
Autor:
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko
Publikováno v:
European Clinical Respiratory Journal, Vol 11, Iss 1 (2024)
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre, r
Externí odkaz:
https://doaj.org/article/3a61695cb0444719be9e00172eb6d4dd